NCT03561402View on ClinicalTrials.gov

Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio)

CompletedOBSERVATIONAL
Enrollment

24

Participants

Timeline

Start Date

December 1, 2016

Primary Completion Date

December 30, 2020

Study Completion Date

December 30, 2020

Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
DRUG

Teriflunomide

Each patient will receive 1 tablet (14 mg) on a daily basis.

Trial Locations (1)

H3A 2B4

Department of Pathology, Montreal

All Listed Sponsors
lead

McGill University

OTHER

NCT03561402 - Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio) | Biotech Hunter | Biotech Hunter